ICD's in Athletes: The Journey Continues

Description

Learn about the evolution of recommendations and management of athletes with ICDs.

Learning Objectives

Describe how recommendations for returning to play may differ by cardiac conditions.
Review updated Guidelines and Consensus statements for returning to play for athletes.
Summarize the role of pharmacotherapy in the management of athletes with ICDs.

Session Chair(s)

Jeanne Poole, MD
Mark Estes, MD

Presentation

Update on Guidelines and Consensus Statement for Athletes with ICDs
Presenter(s): Eugene H. Chung, MD, MPH, MSci

Channelopathies, Cardiomyopathies, Coronary Artery Anomalies, Congenital Heart Disease: Are the Risks the Same?
Presenter(s): Mitchell I. Cohen, MD

Subcutaneous vs. Transvenous ICDs: Pros and Cons
Presenter(s): Ciorsti MacIntyre, MD

Pharmacotherapy for Athletes with ICDs
Presenter(s): Douglas Darden, MD

Disclosures

Eugene Chung:

Nothing Relevant to Disclose

Mitchell Cohen:

Alta Thera Pharmaceuticals (Honoraria/Speaking/Consulting Fee - Consulting)

Ciorsti MacIntyre:

Abbott Medical (Honoraria/Speaking/Consulting Fee - Speaking and Teaching)
Boston Scientific (Honoraria/Speaking/Consulting Fee - Speaking and Teaching)

Douglas Darden:

Nothing Relevant to Disclose

To view all Heart Rhythm 2025 Faculty Disclosures, please click here.

Education Framework

Ventricular Tachyarrhythmias
-- Implantable Cardioverter-defibrillators (ICDs)
-- 224. Know how to determine sudden cardiac death risk in patients with heart disease or risk factors.

Summary


Availability:	No future session


Cost:	FREE


Credit Offered:	No Credit Offered